| Literature DB >> 29316974 |
Khaled Bellassoued1, Anis Ben Hsouna2, Khaled Athmouni3, Jos van Pelt4, Fatma Makni Ayadi5, Tarek Rebai6, Abdelfattah Elfeki7.
Abstract
BACKGROUND: Mentha piperita L. is a flowering plant belonging to the Lamiaceae family. Mentha plants constitute one of the main valuable sources of essential oil used in foods and for medicinal purposes.Entities:
Keywords: Essential oil; Histopathological; Kidney; Liver; M. piperita; Oxidative stress
Mesh:
Substances:
Year: 2018 PMID: 29316974 PMCID: PMC5761127 DOI: 10.1186/s12944-017-0645-9
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Chemical composition (%) of leaves essential oil from Tunisian M.piperita as identified by GC/MS analysis
| Peak | Compounds | Retention Time (min) | Percentage (%) |
|---|---|---|---|
| 1 | α-pinene | 4.42 | 1.80 |
| 2 | β-pinene | 6.07 | 0.14 |
| 3 | Sabinene | 6.42 | 0.25 |
| 4 | Myrcene | 7.81 | 1.30 |
| 5 | Limonene | 8.30 | 8.0 |
| 6 | 1,8-cineole | 8.48 | 2.80 |
| 7 | 3-octanone | 10.13 | 0.45 |
| 8 | 3-octanol | 10.41 | 0.53 |
| 9 | Limonene oxide | 13.44 | 0.59 |
| 10 | α-terpineol | 18.62 | 0.37 |
| 11 | Linalool | 15.73 | 2.64 |
| 12 | iso-menthone | 15.14 | 33.00 |
| 13 | Menthyl acetate | 16.35 | 0.68 |
| 14 | Iso-pulegol | 16.71 | 2.40 |
| 15 | Isomenthol | 17.29 | 0.28 |
| 16 | Neo-iso-menthol | 17.90 | 0.45 |
| 17 | Menthol | 18.25 | 33.59 |
| 18 | Pulegone | 18.39 | 1.6 |
| 19 | Neryl acetate | 18.45 | 0.8 |
| 20 | Piperitone | 19.09 | 3.2 |
| 21 | Myrtenol | 19.56 | 0.55 |
| 22 | Carveol | 19.99 | 0.31 |
| 23 | Caryophyllene | 17.33 | 1.95 |
| 24 | Caryophyllene oxide | 20.10 | 0.11 |
| 25 | Germacrene D | 20.80 | 0.11 |
| 26 | Δ –Cadinene | 21.92 | 0.27 |
| Monoterpene hydrocarbons (%) | 16.23 | ||
| Oxygenated monoterpenes (%) | 79.5 | ||
| Sesquiterpene hydrocarbons (%) | 2.44 | ||
| Total (%) | 98.17 | ||
MpEO effects and positive controls on the in vitro free radical(DPPH and superoxide)
| MpEO | Silymarin | |
|---|---|---|
| 50% scavenging concentration (μg/ml) on DPPH radical | 61.28 ± 0.02* | 21.25 ± 0.13 |
| 50% scavenging concentration (μg/ml) on superoxide anion | 356.45 ± 0.35* | 39.04 ± 1.02 |
Values are represented as mean ± SEM of six different experiments
*p < 0.05 versus silymarin
Effects of CCl4, MpEO and their combination MpEO/CCl4 on hepatic markers in serum of control and experimental rats
| Treatment and parameters | AST (U/L) | ALT (U/L) | ALP (U/L) | LDH (U/L) | γ-GT (U/L) |
|---|---|---|---|---|---|
| Control | 164.82 ± 1.28 | 65.88 ± 1.44 | 149.61 ± 2.19 | 20.81 ± 0.52 | 3.17 ± 0.39 |
| CCl4 | 524.12 ± 5.11*** | 179.23 ± 3.39*** | 217.47 ± 8.55*** | 40.66 ± 0.81*** | 5.43 ± 0.21*** |
| SL/CCl4 | 191.15 ± 2.14### | 87.82 ± 7.61### | 157.50 ± 5.12## | 28.62 ± 0.62### | 3.47 ± 0.06### |
| MpEOa/CCl4 | 479.89 ± 36.41 | 162.02 ± 9.18 | 202.42 ± 7.62 | 37.75 ± 1.35 | 4.45 ± 0.25 |
| MpEOb/CCl4 | 356.82 ± 35.77## | 147.35 ± 5.67## | 186.74 ± 3.98# | 34.16 ± 1.35## | 4.06 ± 0.17## |
| MpEOc/CCl4 | 216.80 ± 7.26### | 97.82 ± 6.98### | 165.96 ± 5.12### | 31.64 ± 5.12### | 3.51 ± 0.20### |
| MpEOc | 160.80 ± 2.47 | 63.08 ± 1.16 | 139.77 ± 7.27 | 19.89 ± 0.18 | 2.81 ± 0.24 |
AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, LDH lacatate dehydrogenase and γGT gamma glutamyl transferase.aMpEO(5 mg/kg BW), bMpEO(15 mg/kg BW), cMpEO(40 mg/kg BW), SL: Silymarin (50 mg/kg BW)
Values are mean ± SEM for eight rats in each group. CCl4, MpEO and MpEO/CCl4 treated groups vs control group; ** p < 0.01, *** p < 0.001, CCl4 group vs MpEO/CCl4 group; # p < 0.05, # # p < 0.01, # # # p < 0.001
Effects of CCl4,MpEO and their combination MpEO/CCl4 on lipid profile in serum of control and experimental rats
| Treatment and parameters | T-Cholesterol (mmol/l) | T-Triglycerides (mmol/l) | HDL (mmol/L) | LDL (mmol/l) |
|---|---|---|---|---|
| Control | 1.133 ± 0.033 | 0.736 ± 0.075 | 1.413 ± 0.023 | 0.123 ± 0.014 |
| CCl4 | 1.750 ± 0.028*** | 1.743 ± 0.078*** | 0.446 ± 0.074*** | 0.726 ± 0.053*** |
| SL/CCl4 | 0.966 ± 0.033### | 1.043 ± 0.012### | 1.240 ± 0.030### | 0.176 ± 0.008### |
| MpEOa/CCl4 | 1.606 ± 0.063 | 1.610 ± 0.041 | 0.690 ± 0.135 | 0.640 ± 0.066 |
| MpEOb/CCl4 | 1.376 ± 0.076## | 1.196 ± 0.039## | 0.873 ± 0.053## | 0.253 ± 0.024## |
| MpEOc/CCl4 | 1.033 ± 0.033### | 1.050 ± 0.010### | 1.296 ± 0.039### | 0.186 ± 0.017### |
| MpEOc | 1.100 ± 0.115 | 0.763 ± 0.069 | 1.210 ± 0.106 | 0.113 ± 0.006 |
TC Total cholesterol (mmol/l), HDL high density lipoprotein (mmol/l), TG triglyceride (mmol/l) and LDL low density lipoprotein (mmol/l). aMpEO (5 mg/kg BW), bMpEO (15 mg/kg BW), cMpEO (40 mg/kg BW), SL: Silymarin (50 mg/kg BW)
Values are mean ± SEM for eight rats in each group. CCl4, MpEO and MpEO/CCl4 treated groups vs control group; ** p < 0.01, *** p < 0.001, CCl4 group vs MpEO/CCl4 group; # p < 0.05, # # p < 0.01, # # # p < 0.001
Effects of CCl4, MpEO and their combination MpEO/CCl4 on kidney markers in serum of control and experimental rats
| Treatment | Urea | Creatinine |
|---|---|---|
| Control | 7.53 ± 0.59 | 11.12 ± 0.30 |
| CCl4 | 15.41 ± 1.57** | 12.79 ± 0.15** |
| SL/CCl4 | 8.04 ± 0.32# # | 11.19 ± 0.27# # |
| MpEOa/CCl4 | 12.52 ± 0.32 | 11.94 ± 0.47 |
| MpEOb/CCl4 | 10.50 ± 0.29# | 11.45 ± 0.40# |
| MpEOc/CCl4 | 9.44 ± 0.67# # | 11.39 ± 0.30# # |
| MpEOc | 7.34 ± 0.38 | 11.27 ± 0.35 |
aMpEO(5 mg/kg BW), bMpEO(15 mg/kg BW), cMpEO(40 mg/kg BW), SL: Silymarin (50 mg/kg BW)
Values are mean ± SEM for ten rats in each group. CCl4, MpEO and MpEO/CCl4 treated groups vs control group; ** p < 0.01, *** p < 0.001, CCl4 group vs MpEO/CCl4group; # p < 0.05, # # p < 0.01, # # # p < 0.001
Fig. 1a Effects of CCl4, MpEO and their combinations MpEO/CCl4 on hepatic TBARS of control (Con) and experimental rats. Con, control group; mod, CCl4-model group; SL/CCl4, silymarin 50 mg/kg + CCl4; MpEO/CCl4 5 mg/kg + CCl4 group; MpEO/CCl4 15 mg/kg + CCl4 group; MpEO/CCl4 40 mg/kg + CCl4 group; MpEO 40 mg/kg group. Values are mean ± SEM for ten rats in each group. CCl4, MpEO, MpEO/CCl4 treated groups vs control group; *p < 0.05, **p < 0.01, *** p < 0.001, CCl4 group vs (MpEO/CCl4) group; #p < 0.05, ##p < 0.01, ###p < 0.001. b. Effects of CCl4, MpEO and their combinations (MpEO/CCl4) on kidney TBARS of control (Con) and experimental rats. Con, control group; mod, CCl4-model group; SL/CCl4, silymarin 50 mg/kg + CCl4; MpEO/CCl4 5 mg/kg + CCl4 group; MpEO/CCl4 15 mg/kg + CCl4 group; MpEO/CCl4 40 mg/kg + CCl4 group; MpEO 40 mg/kg. Values are mean ± SEM for ten rats in each group. CCl4, MpEO, MpEO/CCl4 treated groups vs control group; *p < 0.05, **p < 0.01, *** p < 0.001, CCl4 group vs (MpEO/CCl4) group; #p < 0.05, ##p < 0.01, ###p < 0.001
Effects of CCl4, MpEO and their combination MpEO/CCl4 on the activities of enzymatic antioxidants in liver of control and experimental rats
| Treatment | SOD | CAT | GPx |
|---|---|---|---|
| Control | 16.04 ± 0.11 | 14.03 ± 0.29 | 7.66 ± 0.51 |
| CCl4 | 13.60 ± 0.50*** | 11.13 ± 0.37*** | 5.25 ± 0.25** |
| SL/CCl4 | 15.80 ± 0.50## | 13.48 ± 0.25### | 7.41 ± 0.16### |
| MpEOa/CCl4 | 13.92 ± 0.40 | 11.34 ± 0.41 | 5.41 ± 0.31 |
| MpEOb/CCl4 | 14.98 ± 0.19# | 12.32 ± 0.32# | 6.04 ± 0.17# |
| MpEOc/CCl4 | 15.65 ± 0.44## | 13.20 ± 0.19### | 7.26 ± 0.22### |
| MpEOc | 15.83 ± 0.31 | 13.85 ± 0.33 | 7.45 ± 0.33 |
aMpEO(5 mg/kg BW), bMpEO (15 mg/kg BW), cMpEO(40 mg/kg BW), SL: Silymarin (50 mg/kg BW)
Values are mean ± SEM for ten rats in each group. CCl4, MpEO and MpEO/CCl4 treated groups vs control group; ** p < 0.01, *** p < 0.001, CCl4 group vs MpEO/CCl4 group; # p < 0.05, # # p < 0.01, # # # p < 0.001
Effects of CCl4, MpEO and their combination MpEO/CCl4 on the activities of enzymatic antioxidants in kidney of control and experimental rats
| Treatment | SOD | CAT | GPx |
|---|---|---|---|
| Control | 15.13 ± 0.22 | 12.90 ± 0.15 | 5.68 ± 0.27 |
| CCl4 | 12.12 ± 0.50*** | 10.05 ± 0.34*** | 4.06 ± 0.28** |
| SL/CCl4 | 14.52 ± 0.35## | 12.23 ± 0.24### | 5.56 ± 0.14## |
| MpEOa/CCl4 | 12.92 ± 0.20 | 10.80 ± 0.22 | 4.46 ± 0.33 |
| MpEOb/CCl4 | 13.69 ± 0.10# | 11.02 ± 0.22# | 5.10 ± 0.28# |
| MpEOc/CCl4 | 14.20 ± 0.35## | 12.04 ± 0.19### | 5.32 ± 0.06## |
| MpEOc | 14.91 ± 0.21 | 12.62 ± 0.33 | 5.59 ± 0.27 |
aMpEO(5 mg/kg BW), bMpEO(15 mg/kg BW), cMpEO(40 mg/kg BW), SL: Silymarin (50 mg/kg BW)
Values are mean ± SEM for ten rats in each group. CCl4, MpEO and MpEO/CCl4 treated groups vs control group; ** p < 0.01, *** p < 0.001, CCl4 group vs MpEO/CCl4 group; # p < 0.05, # # p < 0.01, # # # p < 0.001
Fig. 2Effect of MpEO on CCl4-induced liver damage. a Control group; (b) CCl4-model group showing marked inflammatory cells, necrosis and reduced lesions of necrosis; (c) Silymarin 50 mg/kg + CCl4 group; (d) MpEO 5 mg/kg + CCl4 group (e); MpEO 15 mg/kg + CCl4 group; (f) MpEO 40 mg/kg + CCl4 group; (g) MpEO 40 mg/kg group. Hematoxylin/eosin staining; magnification ×400. : Marked inflammatory cells; : Necrosis cells; : Reduced lesions of necrosis; : Regeneration area; : Prominent nucleolus; : Mild inflammatory cells
Grades of inflammatory cells and cellular necrosis in rat liver
| Pathologic grading of inflammatory cells and cellular necrosis | ||||||||
|---|---|---|---|---|---|---|---|---|
| Groups | Zero | I | II | III | IV | N | ||
| Control | 10 | 0 | 0 | 0 | 0 | 10 | – | |
| CCl4*** | 0 | 1 | 3 | 3 | 3 | 10 | – | |
| SL/CCl4### | 8 | 2 | 0 | 0 | 0 | 10 | ns | |
| MpEOa/CCl4 | 0 | 2 | 6 | 1 | 1 | 10 | ns | |
| MpEOb/CCl4# | 6 | 4 | 0 | 0 | 0 | 10 | ns | |
| MpEOc/CCl4### | 7 | 3 | 0 | 0 | 0 | 10 | ns | |
| MpEOc | 9 | 1 | 0 | 0 | 0 | 10 | ns | |
aMpEO (5 mg/kg BW), bMpEO (15 mg/kg BW), cMpEO (40 mg/kg BW), SL: Silymarin (50 mg/kg BW)
Fig. 3Effect of MpEO on CCl4-induced kidney damage. a Control group; (b) CCl4-model group showing some nephrotoxic lesions, as evidenced by the glomerular and tubular necrosis; (c) Silymarin 50 mg/kg + CCl4 group; (d) MpEO 5 mg/kg + CCl4 group (e); MpEO 15 mg/kg + CCl4 group; (f) MpEO 40 mg/kg + CCl4 group; (g) MpEO 40 mg/kg group. Hematoxylin/eosin staining; magnification ×400. : glomerular necrosis; : necrosis in epithelial cells of the proximal tubules
Grades of glomerular and epithelial cells of the proximal tubules necrosis in rat kidney
| Pathologic grading of glomerular and epithelial cells of the proximal tubules necrosis | ||||||||
|---|---|---|---|---|---|---|---|---|
| Groups | Zero | I | II | III | IV | N | ||
| Control | 10 | 0 | 0 | 0 | 0 | 10 | – | |
| CCl4*** | 0 | 2 | 2 | 3 | 3 | 10 | – | |
| SL/CCl4### | 8 | 2 | 0 | 0 | 0 | 10 | ns | |
| MpEOa/CCl4 | 0 | 2 | 5 | 3 | 0 | 10 | ns | |
| MpEOb/CCl4# | 6 | 4 | 0 | 0 | 0 | 10 | ns | |
| MpEOc/CCl4### | 7 | 3 | 0 | 0 | 0 | 10 | ns | |
| MpEOc | 9 | 1 | 0 | 0 | 0 | 10 | ns | |
aMpEO (5 mg/kg BW), bMpEO (15 mg/kg BW), cMpEO (40 mg/kg BW), SL: Silymarin (50 mg/kg BW)